A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
70
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastroesophageal Cancer (GC)
Hepatocellular Carcinoma (HCC)
Endometrial Cancer
Renal Cell Carcinoma (RCC)
Interventions
DRUG:
CTX-10726
Sponsor
Compass Therapeutics